Coherus Oncology Inc (CHRS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Coherus Oncology inc   (NASDAQ: CHRS)


Coherus Oncology Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Coherus Oncology Inc's ROI in the second quarter of 2026?
Coherus Oncology Inc recorded a cumulative net loss of $-132 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -103.32%.

Within the Healthcare sector 632 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 34.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -23.29 % -18.66 % -31.78 % -36.29 % -38.2 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 116 134 118 144 176
Return On Investment (TTM) -103.32 % 130.32 % 121.31 % 103.03 % 107.82 %
CHRS's Overall Ranking # 34 # 34 # 23 # 52 # 39
Seq. Investment Change TTM -10.52 % 3.19 % -7.91 % -9.78 % -5.12 %
Seq. Net Income Change TTM - 10.86 % 8.42 % -13.79 % -
Net Income (TTM) in Millions -132 186 168 155 180

CHRS Company Profile >> Back to CHRS Roi Comparisons >> See Annual CHRS Return On Investment



Return On Investment CHRS's Ranking
Within: No.
Industry # 104
Sector # 633
Overall # 34

Return On Investment Statistics
High Average Low
128.8 %
-61.13 %
-208.17 %
(Mar 31 2026)   (Jun 30 2016)







Financial Statements
Coherus Oncology Inc's II. Quarter Investments $ 116 Millions CHRS's Balance sheet
Coherus Oncology Inc's II. Quarter Income $ -21 Millions Quarterly CHRS's Income Statement
CHRS's Income by Division See CHRS's Income by Division


CHRS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 118 166 298 342 507
Y / Y Investment Growth -28.75 % -44.41 % -12.95 % -32.48 % -26.13 %
Net Income in Millions 168 29 -238 -292 -287
Y / Y Net Income Growth 489.41 % - - - -
Annual Return On Investment 142.45 % 17.22 % -79.87 % -85.27 % -56.65 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 142.45 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CHRS's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CHRS's Competitors
Subscribers only: Roi for Coherus Oncology Inc's Suppliers
Subscribers only: Return On Investment for CHRS's Customers

Other Ratios
CHRS's Roa CHRS's Inventory Turnover Ratio CHRS's Growth Rates CHRS's Dividend Statistics
CHRS's Profitability Ratios CHRS's Asset Turnover Ratio CHRS's Dividend Growth
CHRS's Roe CHRS's Valuation Ratios CHRS's Financial Strength Ratios CHRS's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-11T07:12:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.